APASL consensus statements and management algorithms for hepatitis C virus infection

by Omata, M., Kanda, T., Yu, M.-L., Yokosuka, O., Lim, S.-G., Jafri, W., Tateishi, R., Hamid, S.S., Chuang, W.-L., Chutaputti, A., Wei, L., Sollano, J., Sarin, S.K., Kao, J.-H., McCaughan, G.W.
Published 2016

Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B

by Zeuzem, S., Gane, E., Liaw, Y.-F., Lim, S.G., DiBisceglie, A., Buti, M., Chutaputti, A., Rasenack, J., Hou, J., O'Brien, C., Nguyen, T.T., Jia, J., Poynard, T., Belanger, B., Bao, W., Naoumov, N.V.
Published 2016

Treatment of hepatitis B e antigen-positive chronic hepatitis with telbivudine or adefovir: A randomized trial

by Chan, H.L.Y., Heathcote, E.J., Marcellin, P., Lai, C.-L., Cho, M., Moon, Y.M., Chao, Y.-C., Myers, R.P., Minuk, G.Y., Jeffers, L., Sievert, W., Bzowej, N., Harb, G., Kaiser, R., Qiao, X.-J., Brown, N.A., Crawford, D., Lim, S.-G., Chutaputti, A., Poynard, T.
Published 2016